Literature DB >> 32612424

Paraoxonase Activity and Phenotype Distribution in Patients with Chronic Obstructive Pulmonary Disease.

Nurhan Sarioglu1, Cigdem Bilen2, Celalettin Cevik3, Nahit Gencer4.   

Abstract

OBJECTIVE: Paraoxonase 1 (PON1) and arylesterase (ARE) enzymes have an important role in the prevention of oxidative stress which is related to the pathogenesis of chronic obstructive pulmonary disease (COPD). PON1 levels vary widely among individuals and ethnic groups, which is in part associated with polymorphisms.
MATERIALS AND METHODS: We investigated PON1 and ARE activity and phenotype distribution in COPD patients and healthy individuals. Sixty six COPD patients and 59 control subjects were involved in the study. Serum PON1 and ARE activities were detected by spectrophotometric method. The ratio of salt-induced PON1 to ARE activity was used to determine phenotypes as QQ, QR, and RR.
RESULTS: COPD patients exhibited higher PON1 activity (199.1 vs 129.2, p=0.002) but lower ARE activity compared to control (21.3 vs 33.5, p=0.021). There was a significant difference between COPD and control group with respect to PON1 phenotype characteristics. RR phenotypic distribution was more common in the COPD group than in control (60.6% [95% CI: 48.8 - 72.3] versus 22.0 % [95% CI: 12.0 - 31.9], p=0.001). We also found that smoking (95.0% CI: 0.001-0.036, p<0.001) and RR phenotype (95.0% CI: 0.006 - 0.59, p=0.016) are independent determinants in COPD.
CONCLUSION: We found that RR phenotype was more common in COPD patients compared to control. Smoking and RR phenotype may be defined as independent factors associated with COPD. ©Copyright 2020 by the Atatürk University School of Medicine - Available online at www.eurasianjmed.com.

Entities:  

Keywords:  COPD; paraoxonase 1; phenotype

Year:  2020        PMID: 32612424      PMCID: PMC7311125          DOI: 10.5152/eurasianjmed.2019.19122

Source DB:  PubMed          Journal:  Eurasian J Med        ISSN: 1308-8734


  33 in total

1.  Pulmonary function, oxidative stress and inflammatory markers in severe COPD exacerbation.

Authors:  Ivana Stanojkovic; Jelena Kotur-Stevuljevic; Branislava Milenkovic; Slavica Spasic; Tatjana Vujic; Aleksandra Stefanovic; Aleksandra Llic; Jasmina Ivanisevic
Journal:  Respir Med       Date:  2011-10       Impact factor: 3.415

2.  Evaluation of serum paraoxonase and arylesterase activities in subjects with asthma and chronic obstructive lung disease.

Authors:  A Acay; F Erdenen; E Altunoglu; H Erman; C Muderrisoglu; G G Korkmaz; R Gelisgen; O Tabak; H Uzun
Journal:  Clin Lab       Date:  2013       Impact factor: 1.138

3.  The inverse association of HDL-cholesterol with future risk of hypertension is not modified by its antioxidant constituent, paraoxonase-1: The PREVEND prospective cohort study.

Authors:  Setor K Kunutsor; Lyanne M Kieneker; Stephan J L Bakker; Richard W James; Robin P F Dullaart
Journal:  Atherosclerosis       Date:  2017-06-21       Impact factor: 5.162

4.  Polymorphisms in the human paraoxonase (PON1) promoter.

Authors:  V H Brophy; M D Hastings; J B Clendenning; R J Richter; G P Jarvik; C E Furlong
Journal:  Pharmacogenetics       Date:  2001-02

5.  The human serum paraoxonase/arylesterase polymorphism.

Authors:  H W Eckerson; C M Wyte; B N La Du
Journal:  Am J Hum Genet       Date:  1983-11       Impact factor: 11.025

6.  The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts.

Authors:  H W Eckerson; J Romson; C Wyte; B N La Du
Journal:  Am J Hum Genet       Date:  1983-03       Impact factor: 11.025

7.  Allelic variants of the human scavenger receptor class B type 1 and paraoxonase 1 on coronary heart disease: genotype-phenotype correlations.

Authors:  Francisco Rodríguez-Esparragón; José C Rodríguez-Pérez; Yaridé Hernández-Trujillo; Antonio Macías-Reyes; Alfonso Medina; Araceli Caballero; Carlos M Ferrario
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-01-27       Impact factor: 8.311

Review 8.  Modulation of paraoxonase (PON1) activity.

Authors:  Lucio G Costa; Annabella Vitalone; Toby B Cole; Clement E Furlong
Journal:  Biochem Pharmacol       Date:  2005-02-15       Impact factor: 5.858

Review 9.  Phenotyping Before Starting Treatment in COPD?

Authors:  Nikolaos Siafakas; Alexandru Corlateanu; Evangelia Fouka
Journal:  COPD       Date:  2017-04-07       Impact factor: 2.409

Review 10.  Inflammatory mechanisms in patients with chronic obstructive pulmonary disease.

Authors:  Peter J Barnes
Journal:  J Allergy Clin Immunol       Date:  2016-05-27       Impact factor: 10.793

View more
  4 in total

1.  Suppressed paraoxonase-1 activity associates with elevated oxylipins and the presence of small airways disease in patients with rheumatoid arthritis.

Authors:  Amir A Razmjou; Jennifer M Wang; Ani Shahbazian; Srinivasa Reddy; Christina Charles-Schoeman
Journal:  Clin Rheumatol       Date:  2022-09-22       Impact factor: 3.650

Review 2.  Paraoxonase-1 Concentrations in Obstructive Sleep Apnoea: A Systematic Review and Meta-Analysis.

Authors:  Maria Carmina Pau; Angelo Zinellu; Elisabetta Zinellu; Gianfranco Pintus; Ciriaco Carru; Alessandro G Fois; Arduino A Mangoni; Pietro Pirina
Journal:  Antioxidants (Basel)       Date:  2022-04-12

Review 3.  The Role of Oxidative Stress in Sarcoidosis.

Authors:  Sara Solveig Fois; Sara Canu; Alessandro Giuseppe Fois
Journal:  Int J Mol Sci       Date:  2021-10-28       Impact factor: 5.923

Review 4.  Paraoxonase 1 and Chronic Obstructive Pulmonary Disease: A Meta-Analysis.

Authors:  Jun Watanabe; Kazuhiko Kotani; Alejandro Gugliucci
Journal:  Antioxidants (Basel)       Date:  2021-11-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.